4
Changes in Ownership
Prelude Therapeutics Inc Filed Acc 0001825005-26-000002
Options or other derivatives
- Chief Chemistry Officer acquired 230,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Combs Andrew Chief Chemistry Officer | 2026-02-04 | Grant or award · Employee Stock Option (right to buy) | +230,000 | 230,000 | D | ||
Loading xslF345X05/primarydocument.xml…